文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

疟疾疫苗与单克隆抗体的价值概况

Value profile for Malaria vaccines and monoclonal antibodies.
PubMed 文献 · Vaccine · 2025-11-15

本文由学术界、非营利及多边组织和公私合作机构的专家工作组编写,对疟疾疫苗与预防性单克隆抗体的潜在公共卫生、经济和社会价值进行高层级综合评估;文中提及2021年以来两种疟疾疫苗获世界卫生组织推荐并获全球疫苗免疫联盟资助,试点引入后全因死亡率下降13%、重症疟疾住院下降22%。

要点

  • 2021年以来两种疟疾疫苗获世界卫生组织推荐并获全球疫苗免疫联盟资助,在撒哈拉以南非洲需求旺盛。
  • 试点引入后全因死亡率下降13%,重症疟疾住院下降22%。
  • 单克隆抗体预防已成为有前景的新干预手段,世界卫生组织正制定相关产品特性指南。

核心结论

  • 本价值概况对研发管线中疟疾疫苗与预防性单克隆抗体的潜在公共卫生、经济和社会价值进行了高层级综合评估。

研究设计与样本

  • 由来自学术界、非营利及多边组织和公私合作机构的主题专家工作组编写,基于当前公开可获取的信息与数据进行高层级综合评估。

主要发现

  • 试点引入后全因死亡率下降13%,重症疟疾住院下降22%。
  • 2021年以来两种疟疾疫苗获世界卫生组织推荐并获全球疫苗免疫联盟资助,目前在撒哈拉以南非洲需求旺盛。
  • 单克隆抗体预防已成为有前景的新干预手段,世界卫生组织据此正制定新的指导文件以形成疟疾单克隆抗体的首选产品特性。

关键数值与推荐

  • 世界卫生组织首选产品特性于2022年修订。
  • 世界卫生组织正制定关于疟疾单克隆抗体的新指导文件以形成其首选产品特性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Malaria remains a leading cause of morbidity and mortality and is responsible for over 0.5 million annual deaths globally. During the first two decades of this century, scale-up of a range of tools was associated with significant reductions in malaria mortality in the primary risk group, young African children. However, in recent years progress has stalled and even reversed in some high-burden countries, highlighting the urgent need for new interventions. Since 2021, two malaria vaccines have received World Health Organization (WHO) recommendations and Gavi, the Vaccine Alliance financing and are now in high demand across sub-Saharan Africa. Despite their promise, including a 13 % decline in all-cause mortality and a 22 % drop in severe malaria hospitalizations following pilot introduction, there remains keen interest in developing improved vaccines in alignment with WHO's preferred product characteristics (PPCs), revised in 2022 (see https://www.who.int/publications/i/item/9789240057463). Further, monoclonal antibody (mAb) prophylaxis has emerged as a promising new intervention, which led to WHO's developing a new guidance document to inform PPCs for malaria mAbs (see https://www.who.int/publications/i/item/9789240070981). The priority focus for these aspirational tools is on prevention of disease and death in young African children; however, there is increasing focus on tools that could be deployed across entire populations to break the cycle of parasite transmission and accelerate elimination. Further, accelerated impact of next-generation vaccines is emerging thanks to the pioneering introduction of current vaccines into established national immunization programs and strong coordination with national malaria programs. This vaccine value profile (VVP) for malaria-developed by a working group of subject matter experts from academia, nonprofit and multilateral organizations, and public-private partnerships-provides a high-level, holistic assessment of current, existing information and data that are publicly available to inform the potential public health, economic, and societal value of vaccines and prophylactic mAbs in the development pipeline.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Birkett AJ, Ansah E, Gordon S, et al. Value profile for Malaria vaccines and monoclonal antibodies. Vaccine. 2025. PMID: 41241619. doi:10.1016/j.vaccine.2025.127971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。